IQVIA Holdings Inc
NYSE:IQV

Watchlist Manager
IQVIA Holdings Inc Logo
IQVIA Holdings Inc
NYSE:IQV
Watchlist
Price: 199.39 USD -0.43% Market Closed
Market Cap: 36.2B USD
Have any thoughts about
IQVIA Holdings Inc?
Write Note

IQVIA Holdings Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IQVIA Holdings Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
IQVIA Holdings Inc
NYSE:IQV
Long-Term Debt
$12.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
20%
Thermo Fisher Scientific Inc
NYSE:TMO
Long-Term Debt
$31.2B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Long-Term Debt
$16.3B
CAGR 3-Years
-12%
CAGR 5-Years
0%
CAGR 10-Years
19%
West Pharmaceutical Services Inc
NYSE:WST
Long-Term Debt
$204.8m
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
-4%
Mettler-Toledo International Inc
NYSE:MTD
Long-Term Debt
$1.9B
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
18%
Agilent Technologies Inc
NYSE:A
Long-Term Debt
$3.3B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
7%
No Stocks Found

IQVIA Holdings Inc
Glance View

Market Cap
36.2B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

In the world of healthcare, IQVIA Holdings Inc. emerges as a formidable player, seamlessly blending data analytics with the imperative of human well-being. Born from the merger of IMS Health and Quintiles in 2016, IQVIA stands at the intersection of technology and life sciences, leveraging vast amounts of health-related data to facilitate more informed decisions in drug development and patient care. The company's vast repository consists of a complex tapestry of dynamic insights from around the globe, which it transforms using sophisticated analytical tools. This technical prowess enables IQVIA to offer solutions that span clinical trials, health information services, and advanced analytics, creating substantial value for pharmaceutical and life sciences companies. At the heart of IQVIA’s revenue model lies its ability to provide strategic services that reduce the time and cost associated with the development of new pharmaceuticals. By offering an integrated suite of services from the initial phases of drug research to post-market monitoring, IQVIA assists its clients in navigating regulatory landscapes and commercializing their products effectively. Its expansive technological infrastructure does not just aid in drug development but also enhances patient engagement, creating digital pathways for more personalized healthcare solutions. Thus, IQVIA earns its keep by not only selling information but also by offering transformative insights that sharpen the competitive edge for its clients in the ever-evolving healthcare sector.

IQV Intrinsic Value
266.61 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is IQVIA Holdings Inc's Long-Term Debt?
Long-Term Debt
12.3B USD

Based on the financial report for Sep 30, 2024, IQVIA Holdings Inc's Long-Term Debt amounts to 12.3B USD.

What is IQVIA Holdings Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
20%

Over the last year, the Long-Term Debt growth was 0%. The average annual Long-Term Debt growth rates for IQVIA Holdings Inc have been 1% over the past three years , 1% over the past five years , and 20% over the past ten years .

Back to Top